Mercer Global Advisors
NKTR icon

Mercer Global Advisors’s Nektar Therapeutics NKTR Stock Holding History

Mercer Global Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-776
Closed -$7.92K – 2338
2025
Q1 		$7.92K Buy
+776
New +$10.1K ﹤0.01% 2140
2023
Q4 		– Sell
-1,137
Closed -$10K – 2062
2023
Q3 		$10K Buy
+1,137
New +$10.9K ﹤0.01% 1941
2019
Q3 		– Sell
-394
Closed -$210K – 1178
2019
Q2 		$210K Sell
394
-11
-3% -$5.52K 0.01% 1037
2019
Q1 		$204K Buy
+405
New +$240K 0.01% 979

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mercer Global Advisors's NKTR Position: Q2 2025 in Review

Mercer Global Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 776 shares — an estimated $7.92K sold.

Mercer Global Advisors first reported a position in NKTR in Q1 2019 and held it in 4 quarters. The position peaked at $210K in Q2 2019. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Mercer Global Advisors reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mercer Global Advisors sold 776 Nektar Therapeutics shares in Q2 2025, an estimated $7.92K.
  • Mercer Global Advisors first reported a position in Nektar Therapeutics in Q1 2019 and held it in 4 quarters.
  • Mercer Global Advisors's Nektar Therapeutics position peaked at $210K in Q2 2019.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Mercer Global Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.